Nektar's Rezpegaldesleukin Shows Durable Efficacy in Alopecia and…

Event summary

Rezpegaldesleukin maintained SALT Score ≤20 in 63% of alopecia areata patients six months after treatment cessation.
Atopic dermatitis patients showed 2- to 5-fold increase in complete skin clearance (EASI-100) with monthly/quarterly dosing.
Nektar initiated a third Phase 3 study for treatment-experienced atopic dermatitis patients and plans to start Phase 3 ZENITH AA study in early 2027.
Safety profile remained favorable across both indications through 52 weeks of treatment.

The big picture

Nektar's data suggests rezpegaldesleukin could become a first-line treatment for alopecia areata and atopic dermatitis, addressing significant unmet needs in durable disease control. The Phase 3 expansion into treatment-experienced atopic dermatitis patients positions the company to compete in a growing market for advanced dermatologic therapies. The regulatory fast track designations for both indications may accelerate potential approvals.

What we're watching

Regulatory Pathway: Whether the Phase 3 data will support accelerated approval pathways for both indications.
Market Differentiation: How rezpegaldesleukin's durability compares to existing JAK inhibitors and biologics in these indications.
Commercial Strategy: The pace at which Nektar can expand into treatment-experienced atopic dermatitis patients.